KLF4 and atherosclerosis: We also reveal that trimethylamine-N-oxide (TMAO), a gut-microbiota-dependent metabolite, which is shown to enhance atherosclerosis in animal models and is associated with cardiovascular risks in clinical studies25, induces the glycolytic shift and phenotypic switching of VSMCs in vitro and in vivo by upregulating KLF4 expression.